Hashimoto Shinichiro, Itoh Michihiro, Nishimura Miki, Asai Takayoshi
Department of Transfusion Medicine, Chiba University Hospital, Chiba City, Chiba, Japan.
Ther Apher. 2002 Dec;6(6):431-6. doi: 10.1046/j.1526-0968.2002.00467.x.
To obtain a better (optimal) schedule of peripheral blood stem cell (PBSC) collection by steady-state granulocyte colony-stimulating factor administrations for autologous or allogeneic transplantations, we compared the effect of doses of filgrastim (8 microg/kg/day versus 16 microg/kg/day) for the steady-state mobilization of PBSCs. The effects of a filgrastim dose of 8 microg/kg/day were not significantly different from those of a dose of 16 microg/kg/day. In the group of patients receiving 8 microg/kg/day, the CD34+ cells over 3 x 10(6)/kg donor body weight were harvested in 3 patients who did not have a long history of receiving combination chemotherapy. The administration of 8 microg/kg filgrastim was adopted also for allogeneic PBSC mobilization for 24 healthy donors. All healthy donors donated an adequate number of PBSCs (CD34+ cells over 4 x 10(6)/kg of recipient body weight) and tolerated this mobilization well with no serious complications. In PBSC mobilization with healthy donors, the maximal yields of CD34+ cells from Day 4 to Day 6 were seen on the fifth day in most cases.
为了通过稳态粒细胞集落刺激因子给药获得更好（最佳）的外周血干细胞（PBSC）采集方案用于自体或异体移植，我们比较了非格司亭剂量（8微克/千克/天与16微克/千克/天）对PBSC稳态动员的影响。8微克/千克/天的非格司亭剂量与16微克/千克/天的剂量效果无显著差异。在接受8微克/千克/天的患者组中，3例没有接受联合化疗长期病史的患者收获了超过3×10⁶/千克供体体重的CD34⁺细胞。8微克/千克非格司亭的给药方案也用于24名健康供体的异体PBSC动员。所有健康供体均捐献了足够数量的PBSC（超过4×10⁶/千克受体体重的CD34⁺细胞），并且对这种动员耐受良好，没有严重并发症。在健康供体的PBSC动员中，大多数情况下，第4天至第6天CD34⁺细胞的最大产量出现在第5天。
